|
시장보고서
상품코드
1762314
세계의 전립선암 바이오마커 시장, 규모, 점유율, 산업 분석 보고서 : 유형별, 용도별, 최종 용도별, 지역별, 예측(2025-2034년)Prostate Cancer Biomarker Market Size, Share, & Industry Analysis Report: By Type (Genetic Biomarkers, Protein Biomarkers, Cell-Based Biomarkers, and Metabolomic Biomarkers), By Application, By End Use, and By Region - Market Forecast, 2025-2034 |
||||||
Polaris Market Research의 최신 조사에 따르면, 전립선암 바이오마커 시장 규모는 2034년까지 155억 8,000만 달러에 달할 것으로 예측됩니다. 이 보고서는 현재 시장 역학에 대한 상세한 통찰력과 향후 시장 성장에 대한 분석을 제공합니다.
전립선암 바이오마커는 전립선암의 존재, 병기, 진행을 확인하는 데 도움이 되는 체액 및 조직 유래의 분자 지표입니다. 유전체학, 단백질체학, 대사체학에서 AI와 같은 멀티오믹스 접근법의 통합으로 진단 정확도 향상과 질병 계층화가 진행되어 시장 수요를 더욱 촉진하고 있습니다. 이러한 광범위한 프로파일링 기술은 더 높은 민감도와 특이성을 가진 새로운 바이오마커의 발견을 가능하게 하고, 보다 정확한 환자 분류와 맞춤형 치료 전략을 지원합니다. 멀티오믹스 기반 바이오마커 플랫폼의 채택은 맞춤형 암 치료에 대한 관심이 높아지면서 임상 및 연구 분야에서 점점 더 중심적인 역할을 하고 있습니다.
비침습적, 저침습적 진단 기술의 발전이 시장 개척을 촉진하고 있습니다. 액체 생검은 혈액이나 소변 샘플을 통해 전립선암을 감지하고 모니터링할 수 있다는 점에서 기존의 조직 생검을 대체할 수 있는 보다 안전하고 편리한 방법으로 각광받고 있습니다. 이러한 방법은 환자의 순응도를 향상시키고, 실시간 질병 모니터링과 치료법 조정을 가능하게 합니다. 의료 시스템이 조기 발견과 덜 침습적인 진단을 우선시함에 따라 이러한 혁신 기술에 대한 수요는 지속적으로 증가하고 있으며, 전립선암 관리의 혁신에 있어 첨단 바이오마커 기술의 역할이 강화되고 있습니다.
전립선암 바이오마커 시장 보고서 - 주요 내용
유형별로는 단백질 바이오마커 분야가 2024년 가장 큰 시장 점유율을 차지했으며, 이는 광범위한 임상 적용과 여러 단계의 질병 관리 단계에 걸쳐 확립된 검증을 뒷받침하는 것으로 분석됐습니다.
용도별로는 개인맞춤형 치료 접근법과 정밀치료의 도입이 확대됨에 따라 동반진단 분야가 가장 빠르게 확대될 것으로 예측됩니다.
2024년 북미는 전립선암 바이오마커 시장에서 가장 큰 매출 점유율을 유지했는데, 이는 정교한 의료 시스템, 질병에 대한 인식 증가, 진단 및 바이오 제약 기업의 집적에 기인합니다.
아시아태평양 시장은 헬스케어 지식의 향상, 진단 능력 시장 개척, 신흥국의 암 발병률 증가에 힘입어 예측 기간 동안 가장 빠른 시장 성장을 달성할 것으로 예측됩니다.
주요 세계 기업으로는 Arquer Diagnostics, Beckman Coulter, Bio-Techne, DiaCarta, Exact Sciences Corporation, ExoDx, Genomic Health, GenPath, Oncology, MDxHealth, Myriad Genetics, Nucleix, OPKO Health, Proteomedix, Veracyte Oncology, MDxHealth, Myriad Genetics, Nucleix, OPKO Health, Proteomedix, Veracyte 등이 있습니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 세계의 전립선암 바이오마커 시장 인사이트
- 시장 현황
- 전립선암 바이오마커 시장 역학
- 성장 촉진요인과 기회
- 성장 억제요인과 과제
- 여론과 프라이버시에 관한 판례
- PESTEL 분석
- 전립선암 바이오마커 시장 동향
- 밸류체인 분석
제5장 세계의 전립선암 바이오마커 시장 : 유형별
- 주요 조사 결과
- 서론
- 유전자 바이오마커
- 단백질 바이오마커
- 세포 기반 바이오마커
- 대사체학 바이오마커
제6장 세계의 전립선암 바이오마커 시장 : 용도별
- 주요 조사 결과
- 서론
- 스크리닝 및 조기 발견
- 진단 및 리스크 계층화
- 예후 및 치료 모니터링
- 동반진단
제7장 세계의 전립선암 바이오마커 시장 : 최종 용도별
- 주요 조사 결과
- 서론
- 병원 및 진단실험실
- 학술연구기관
- 바이오의약품 기업
제8장 세계의 전립선암 바이오마커 시장 : 지역별
- 주요 조사 결과
- 서론
- 전립선암 바이오마커 시장 분석 : 지역별, 2020-2034년
- 북미
- 북미 : 유형별, 2020-2034년
- 북미 : 용도별, 2020-2034년
- 북미 : 최종 용도별, 2020-2034년
- 미국
- 캐나다
- 유럽
- 유럽 : 유형별, 2020-2034년
- 유럽 : 용도별, 2020-2034년
- 유럽 : 최종 용도별, 2020-2034년
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양 : 유형별, 2020-2034년
- 아시아태평양 : 용도별, 2020-2034년
- 아시아태평양 : 최종 용도별, 2020-2034년
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 유형별, 2020-2034년
- 중동 및 아프리카 : 용도별, 2020-2034년
- 중동 및 아프리카 : 최종 용도별, 2020-2034년
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 남아프리카공화국
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카 : 유형별, 2020-2034년
- 라틴아메리카 : 용도별, 2020-2034년
- 라틴아메리카 : 최종 용도별, 2020-2034년
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제9장 경쟁 구도
- 확대와 인수 분석
- 확대
- 인수
- 제휴/협업/합의/공개
제10장 기업 개요
- AlterG, Inc.
- Biodex Medical Systems, Inc.
- Caremax Prostate Cancer Biomarker Ltd.
- DJO Global
- Drive DeVilbiss Healthcare
- Ekso Bionics
- GF Health Products, Inc.
- Hocoma AG
- Hospital Equipment Mfg. Co
- Invacare Corporation
- Maddak, Inc.
- Ottobock
- Patterson Medical(now Ability Dynamics)
- Rifton Equipment
- TheraBand(Performance Health)
The prostate cancer biomarkers market size is expected to reach USD 15.58 billion by 2034, according to a new study by Polaris Market Research. The report "Prostate Cancer Biomarker Market Share, Size, & Industry Analysis Report: By Type (Genetic Biomarkers, Protein Biomarkers, Cell-Based Biomarkers, and Metabolomic Biomarkers), By application, By End Use, and By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Prostate cancer biomarkers are molecular indicators derived from bodily fluids or tissues that aid in identifying the presence, stage, or progression of prostate cancer. The integration of multi-omics approaches such as AI in genomics, proteomics, and metabolomics to improve diagnostic precision and disease stratification further boosts the market demand. These wide profiling techniques allow the discovery of novel biomarkers with greater sensitivity and specificity, supporting more accurate patient categorization and tailored treatment strategies. The adoption of multi-omics-driven biomarker platforms is becoming increasingly central to clinical and research settings as the focus on individualized cancer care intensifies.
The advancement of noninvasive and minimally invasive diagnostic techniques is boosting the market development. Liquid biopsies are gaining traction for their ability to detect and monitor prostate cancer using blood or urine samples, offering a safer and more convenient alternative to traditional tissue biopsies. These methods improve patient compliance and allow for real-time disease monitoring and therapy adjustment. The demand for such innovations continues to grow as healthcare systems prioritize early detection and less invasive diagnostics, reinforcing the role of advanced biomarker technologies in transforming prostate cancer management.
Prostate Cancer Biomarker Market Report Highlights
In terms of type, the protein biomarkers segment accounted for the largest market share in 2024, supported by their extensive clinical applications and well-established validation across multiple disease management phases.
Based on application, the companion diagnostics segment is anticipated to experience the most rapid expansion, propelled by growing implementation of personalized treatment approaches and precision therapies.
In 2024, North America maintained the largest revenue share of the prostate cancer biomarker market, owing to its sophisticated healthcare systems, elevated disease awareness, and concentration of diagnostic and biopharmaceutical firms.
The Asia Pacific market is projected to achieve the fastest market growth during the forecast period, driven by improving healthcare knowledge, developing diagnostic capabilities, and increasing cancer prevalence in emerging nations.
A few global key market players include Arquer Diagnostics; Beckman Coulter, Inc.; Bio-Techne; DiaCarta; Exact Sciences Corporation; ExoDx; Genomic Health; GenPath Oncology; MDxHealth; Myriad Genetics, Inc.; Nucleix; OPKO Health, Inc.; Proteomedix; and Veracyte, Inc.
Polaris Market Research has segmented the prostate cancer biomarker market report on the basis of type, application, end use, and region:
By Type Outlook (Revenue, USD Billion, 2020-2034)
Genetic Biomarkers
Protein Biomarkers
Cell-based Biomarkers
Metabolomic Biomarkers
By Application Outlook (Revenue, USD Billion, 2020-2034)
Screening and Early Detection
Diagnosis and Risk Stratification
Prognosis and Treatment Monitoring
Companion Diagnostics
By End Use Outlook (Revenue, USD Billion, 2020-2034)
Hospitals & Diagnostic Laboratories
Academic & Research Institutes
Biopharmaceutical Companies
By Regional Outlook (Revenue, USD Billion, 2020-2034)
North America
US
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Vietnam
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Prostate Cancer Biomarker Market Insights
- 4.1. Prostate Cancer Biomarker Market - Market Snapshot
- 4.2. Prostate Cancer Biomarker Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Rising Prevalence of Prostate Cancer and Aging Populations
- 4.2.1.2. Advancements in Biomarker Technologies
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High Cost of Biomarker Development and Testing
- 4.2.3. Public opinion and privacy legal precedents
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Prostate Cancer Biomarker Market Trends
- 4.6. Value Chain Analysis
5. Global Prostate Cancer Biomarker Market, by Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 5.3. Genetic Biomarkers
- 5.3.1. Global Prostate Cancer Biomarker Market, by Genetic Biomarkers, by Region, 2020-2034 (USD Billion)
- 5.4. Protein Biomarkers
- 5.4.1. Global Prostate Cancer Biomarker Market, by Protein Biomarkers, by Region, 2020-2034 (USD Billion)
- 5.5. Cell-based Biomarkers
- 5.5.1. Global Prostate Cancer Biomarker Market, by Cell-based Biomarkers, by Region, 2020-2034 (USD Billion)
- 5.6. Metabolomic Biomarkers
- 5.6.1. Global Prostate Cancer Biomarker Market, by Metabolomic Biomarkers, by Region, 2020-2034 (USD Billion)
6. Global Prostate Cancer Biomarker Market, by Application
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 6.3. Screening and Early Detection
- 6.3.1. Global Prostate Cancer Biomarker Market, by Screening and Early Detection, by Region, 2020-2034 (USD Billion)
- 6.4. Diagnosis and Risk Stratification
- 6.4.1. Global Prostate Cancer Biomarker Market, by Diagnosis and Risk Stratification, by Region, 2020-2034 (USD Billion)
- 6.5. Prognosis and Treatment Monitoring
- 6.5.1. Global Prostate Cancer Biomarker Market, by B-Arrestin Functional Assays, by Region, 2020-2034 (USD Billion)
- 6.6. Companion Diagnostics
- 6.6.1. Global Prostate Cancer Biomarker Market, by Companion Diagnostics, by Region, 2020-2034 (USD Billion)
7. Global Prostate Cancer Biomarker Market, by End Use
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 7.3. Hospitals & Diagnostic Laboratories
- 7.3.1. Global Prostate Cancer Biomarker Market, by Hospitals & Diagnostic Laboratories, by Region, 2020-2034 (USD Billion)
- 7.4. Academic & Research Institutes
- 7.4.1. Global Prostate Cancer Biomarker Market, by Academic & Research Institutes, by Region, 2020-2034 (USD Billion)
- 7.5. Biopharmaceutical Companies
- 7.5.1. Global Prostate Cancer Biomarker Market, by Biopharmaceutical Companies, by Region, 2020-2034 (USD Billion)
8. Global Prostate Cancer Biomarker Market, by Geography
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Prostate Cancer Biomarker Market Assessment, By Geography, 2020-2034 (USD Billion)
- 8.3. Prostate Cancer Biomarker Market - North America
- 8.3.1. North America: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.3.2. North America: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.3.3. North America: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.3.4. Prostate Cancer Biomarker Market - US
- 8.3.4.1. US: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.3.4.2. US: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.3.4.3. US: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.3.5. Prostate Cancer Biomarker Market - Canada
- 8.3.5.1. Canada: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.3.5.2. Canada: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.3.5.3. Canada: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.4. Prostate Cancer Biomarker Market - Europe
- 8.4.1. Europe: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.4.2. Europe: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.4.3. Europe: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.4.4. Prostate Cancer Biomarker Market - UK
- 8.4.4.1. UK: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.4.4.2. UK: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.4.4.3. UK: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.4.5. Prostate Cancer Biomarker Market - France
- 8.4.5.1. France: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.4.5.2. France: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.4.5.3. France: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.4.6. Prostate Cancer Biomarker Market - Germany
- 8.4.6.1. Germany: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.4.6.2. Germany: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.4.6.3. Germany: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.4.7. Prostate Cancer Biomarker Market - Italy
- 8.4.7.1. Italy: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.4.7.2. Italy: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.4.7.3. Italy: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.4.8. Prostate Cancer Biomarker Market - Spain
- 8.4.8.1. Spain: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.4.8.2. Spain: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.4.8.3. Spain: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.4.9. Prostate Cancer Biomarker Market - Netherlands
- 8.4.9.1. Netherlands: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.4.9.2. Netherlands: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.4.9.3. Netherlands: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.4.10. Prostate Cancer Biomarker Market - Russia
- 8.4.10.1. Russia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.4.10.2. Russia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.4.10.3. Russia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.4.11. Prostate Cancer Biomarker Market - Rest of Europe
- 8.4.11.1. Rest of Europe: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.4.11.2. Rest of Europe: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.4.11.3. Rest of Europe: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.5. Prostate Cancer Biomarker Market - Asia Pacific
- 8.5.1. Asia Pacific: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.5.2. Asia Pacific: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.5.3. Asia Pacific: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.5.4. Prostate Cancer Biomarker Market - China
- 8.5.4.1. China: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.5.4.2. China: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.5.4.3. China: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.5.5. Prostate Cancer Biomarker Market - India
- 8.5.5.1. India: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.5.5.2. India: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.5.5.3. India: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.5.6. Prostate Cancer Biomarker Market - Malaysia
- 8.5.6.1. Malaysia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.5.6.2. Malaysia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.5.6.3. Malaysia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.5.7. Prostate Cancer Biomarker Market - Japan
- 8.5.7.1. Japan: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.5.7.2. Japan: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.5.7.3. Japan: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.5.8. Prostate Cancer Biomarker Market - Indonesia
- 8.5.8.1. Indonesia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.5.8.2. Indonesia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.5.8.3. Indonesia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.5.9. Prostate Cancer Biomarker Market - South Korea
- 8.5.9.1. South Korea: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.5.9.2. South Korea: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.5.9.3. South Korea: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.5.10. Prostate Cancer Biomarker Market - Australia
- 8.5.10.1. Australia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.5.10.2. Australia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.5.10.3. Australia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.5.11. Prostate Cancer Biomarker Market - Rest of Asia Pacific
- 8.5.11.1. Rest of Asia Pacific: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.5.11.2. Rest of Asia Pacific: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.5.11.3. Rest of Asia Pacific: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.6. Prostate Cancer Biomarker Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.6.2. Middle East & Africa: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.6.3. Middle East & Africa: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.6.4. Prostate Cancer Biomarker Market - Saudi Arabia
- 8.6.4.1. Saudi Arabia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.6.4.2. Saudi Arabia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.6.4.3. Saudi Arabia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.6.5. Prostate Cancer Biomarker Market - UAE
- 8.6.5.1. UAE: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.6.5.2. UAE: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.6.5.3. UAE: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.6.6. Prostate Cancer Biomarker Market - Israel
- 8.6.6.1. Israel: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.6.6.2. Israel: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.6.6.3. Israel: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.6.7. Prostate Cancer Biomarker Market - South Africa
- 8.6.7.1. South Africa: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.6.7.2. South Africa: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.6.7.3. South Africa: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.6.8. Prostate Cancer Biomarker Market - Rest of Middle East & Africa
- 8.6.8.1. Rest of Middle East & Africa: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.6.8.2. Rest of Middle East & Africa: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.6.8.3. Rest of Middle East & Africa: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.7. Prostate Cancer Biomarker Market - Latin America
- 8.7.1. Latin America: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.7.2. Latin America: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.7.3. Latin America: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.7.4. Prostate Cancer Biomarker Market - Mexico
- 8.7.4.1. Mexico: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.7.4.2. Mexico: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.7.4.3. Mexico: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.7.5. Prostate Cancer Biomarker Market - Brazil
- 8.7.5.1. Brazil: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.7.5.2. Brazil: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.7.5.3. Brazil: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.7.6. Prostate Cancer Biomarker Market - Argentina
- 8.7.6.1. Argentina: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.7.6.2. Argentina: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.7.6.3. Argentina: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
- 8.7.7. Prostate Cancer Biomarker Market - Rest of Latin America
- 8.7.7.1. Rest of Latin America: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
- 8.7.7.2. Rest of Latin America: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
- 8.7.7.3. Rest of Latin America: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. AlterG, Inc.
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Biodex Medical Systems, Inc.
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Caremax Prostate Cancer Biomarker Ltd.
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. DJO Global
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Drive DeVilbiss Healthcare
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Ekso Bionics
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. GF Health Products, Inc.
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Hocoma AG
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Hospital Equipment Mfg. Co
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Invacare Corporation
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
- 10.11. Maddak, Inc.
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development
- 10.12. Ottobock
- 10.12.1. Company Overview
- 10.12.2. Financial Performance
- 10.12.3. Product Benchmarking
- 10.12.4. Recent Development
- 10.13. Patterson Medical (now Ability Dynamics)
- 10.13.1. Company Overview
- 10.13.2. Financial Performance
- 10.13.3. Product Benchmarking
- 10.13.4. Recent Development
- 10.14. Rifton Equipment
- 10.14.1. Company Overview
- 10.14.2. Financial Performance
- 10.14.3. Product Benchmarking
- 10.14.4. Recent Development
- 10.15. TheraBand (Performance Health)
- 10.15.1. Company Overview
- 10.15.2. Financial Performance
- 10.15.3. Product Benchmarking
- 10.15.4. Recent Development
